Skip to content

D&A at other companies

PDE
Pro-Dex, Inc.PDEX
$363K+17.2%
CONMED logo
CONMEDCNMD
$8.7M0.0%
Globus Medical logo
Globus MedicalGMED
$29.53M-55.3%
Enovis logo
EnovisENOV
$41.9M+0.2%
Xtant Medical Holdings logo
Xtant Medical HoldingsXTNT
$534K-50.3%
Medtronic logo
MedtronicMDT
$716M-14.8%

Segments

By geography

See full
Americas$44.9M+10.3%
Corporate Items$31.2M-2.2%
EMEA$16.5M+5.8%
Asia Pacific$15.3M+0.7%

Other financials

Income statement

See full
Revenue$2.1B+9.3%
Gross profit$1.5B+11.1%
Operating income$373.2M+27.7%
Net income$238.1M+30.8%
EPS (diluted)$1.22+34.1%

Balance sheet

See full
Cash & equivalents$424.2M-69.4%
Total debt$7.5B+4.1%
Total equity$12.7B+2.2%
Total assets$22.7B+2.4%

Cash flow

See full
Operating cash flow$359.4M-6.1%
CapEx$36.3M-18.6%
Free cash flow$323.1M-4.5%

Valuation

See full
Market cap$17.81B-6.2%
Enterprise value$24.86B-4.4%
P/E23.4×+0.3×
P/S2.1×-0.3×

Profitability

See full
Gross margin70%-1.0pp
Operating margin14%-3.0pp
Net margin9.1%-2.8pp
FCF margin17.3%-1.6pp

Returns & leverage

See full
Return on equity6.1%-1.2pp
Debt / equity0.6×0.0×
Current ratio1.7×-0.7×

Where this comes from

Reported directly by Zimmer Biomet Holdings in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.

The official record: Zimmer Biomet Holdings’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zimmer Biomet Holdings's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zimmer Biomet Holdings's D&A?
Zimmer Biomet Holdings (ZBH) reported D&A of $162.1M in Q1 2026.
How has Zimmer Biomet Holdings's D&A changed year-over-year?
Zimmer Biomet Holdings's D&A increased by 7.4% year-over-year, from $151M to $162.1M.
What is the long-term trend for Zimmer Biomet Holdings's D&A?
Over 4 years (2021 to 2025), Zimmer Biomet Holdings's D&A has grown at a 5.9% compound annual growth rate (CAGR), from $529.5M to $665.8M.
What does D&A mean?
Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.